Hanall announces supply agreement with Chinese firm over H1N1 vaccine

Published: 2009-11-13 06:56:00

Updated: 2009-11-13 06:56:00

In an effort to secure an adequate supply of the vaccine, Korea's Hanall Pharmaceutical Co. signed a memorandum of understanding with Ealong Biotech Ltd., a Chinese vaccine maker, on November 11 to purchase as many as 60 million doses, enough to inoculate some 6 million people against the H1N1 vi...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK